Rimiterol (INN/USAN) is a third-generation short-acting β2 agonist.
via PubMed
{{Drugbox | Verifiedfields = changed | verifiedrevid = 464382597 | IUPAC_name = 4-{(S)-hydroxy[(2R)-piperidin-2-yl]methyl}benzene-1,2-diol | image = Rimiterol.svg | image_class = skin-invert-image | width = 200 | image2 = Rimiterol ball-and-stick model.png | image_class2 = bg-transparent
| tradename = | pregnancy_AU = A | pregnancy_US = | pregnancy_category = | legal_AU = S4 | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = 32953-89-2 | ATC_prefix = R03 | ATC_suffix = AC05 | ATC_supplemental = | PubChem = 36283 | ChEMBL_Ref = | ChEMBL = 1097630 | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 33366 | UNII_Ref = | UNII = 26GIW6ZLPH
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).